Primary purpose: To evaluate the anti-tumor activity (ORR) of HZ-H08905 in patients with relapsed and/or refractory peripheral T-cell lymphoma
Secondary purposes: 1) Other effectiveness evaluation indicators of HZ-H08905 in patients with relapsed and/or refractory peripheral T-cell lymphoma: CR rate, DCR, TTR, DOR, PFS, OS. 2) Evaluate the safety of HZ-H08905 in the treatment of patients with relapsed and/or refractory peripheral T-cell lymphoma. 3) Evaluate the peripheral blood pharmacokinetic characteristics of HZ-H08905.
[Translation] Phase I clinical study of safety/tolerability and pharmacokinetics of HZ-H08905 in patients with relapsed or refractory non-Hodgkin lymphoma
Main objectives: 1) To evaluate the safety/tolerability of HZ-H08905 in patients with relapsed or refractory non-Hodgkin lymphoma; 2) To determine the maximum tolerated dose (MTD) of HZ-H08905 and the recommended dose in phase II clinical trials (RP2D). Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of HZ-H08905 in patients with relapsed or refractory non-Hodgkin lymphoma; 2) to preliminarily evaluate HZ-H08905 in relapsed or refractory non-Hodgkin lymphoma. Efficacy in patients with gold lymphoma.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.